India's Alkem Lab slips; analysts flag limited margin growth as R&D spend rises

Alkem Laboratories

30/05/2025 07:42

** Pharma products manufacturer Alkem Laboratories ALKE.NS falls 3.85% to 5090.5 rupees after Q4 results

** Co's Q4 revenue profit rises 4% y/y but at least 4 brokerages say it is below expectations

** Jefferies says Alkem's sales growth in India and the U.S. was below expectations

** Adds, co's quest to improve sales will come at the cost of margins as R&D spend rises

** Ambit Capital says price erosion in U.S. markets continues, given limited new launches

** Motilal Oswal flags lack of growth catalysts over FY25-27, given the time it will take for sales growth initiatives to materialize

** ICICI Securities expects nominal margin expansion over FY25-27

 (Reporting by Ananta Agarwal in Bengaluru)

 ((Ananta.Agarwal@thomsonreuters.com))